β Scribed by Maria Domenica Cappellini
No coin nor oath required. For personal study only.
Deferasirox is an oral iron chelator, with a long half-life, that can be given once daily, because it provides a 24-hour chelation. Several phase II trials and a pivotal phase III trial have established that, in transfusion-dependent patients with beta-thalassaemia major, deferasirox has a similar efficacy to previously available deferoxamine. A deferasirox dose of 20 mg/kg/day stabilizes serum ferritin levels and liver iron concentration, while a dose of 30 mg/kg/day reduces serum ferritin and liver iron concentration and achieves negative iron balance. Efficacy has also been shown across various transfusion-dependent anaemias including myelodysplastic syndromes, sickle cell disease, and other rare transfusion-dependent anaemias. Deferasirox is generally well tolerated, with the most common adverse events being gastrointestinal disturbances and rash. Longer-term studies with a median follow-up of 3.5 years have confirmed the efficacy and safety of deferasirox. It is recommended that patients treated with deferasirox are monitored regularly for iron status and adverse events, to ensure that an effective and tolerable iron chelation regimen is established for each individual patient.
π SIMILAR VOLUMES
## Abstract To determine the longβterm efficacy of botulinum toxin (BTX) treatments, we analyzed longitudinal followβup data on 45 patients (32 women; mean age, 68.8 years) currently followed in the Baylor College of Medicine Movement Disorders Clinic, who have received BTX treatments continuously
## Abstract This subgroup analysis of the 6βmonth, openβlabel Switch to Risperidone Microspheres (StoRMi) trial evaluated longβterm safety and efficacy of a direct conversion to risperidone longβacting injectable (RLAI) in 52 elderly patients (β₯65 years) with psychosis stabilized on oral or depot a
## Abstract Research in vitro and in animal models suggested that gold electroplating of stents can attenuate neointimal hyperplasia and reduce thrombogenicity. The objective of this study was to evaluate the safety and efficacy of the goldβcoated NIROYAL stent in the treatment of stenosed coronary